摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6H-Pyrrolo(2,3-d)pyrimidin-6-one, 5,7-dihydro-7-methyl-2-(1-piperidinyl)-, (Z)-2-butenedioate (1:1) | 122113-44-4

中文名称
——
中文别名
——
英文名称
6H-Pyrrolo(2,3-d)pyrimidin-6-one, 5,7-dihydro-7-methyl-2-(1-piperidinyl)-, (Z)-2-butenedioate (1:1)
英文别名
(E)-but-2-enedioic acid;7-methyl-2-piperidin-1-yl-5H-pyrrolo[2,3-d]pyrimidin-6-one
6H-Pyrrolo(2,3-d)pyrimidin-6-one, 5,7-dihydro-7-methyl-2-(1-piperidinyl)-, (Z)-2-butenedioate (1:1)化学式
CAS
122113-44-4
化学式
C16H20N4O5
mdl
——
分子量
348.35
InChiKey
IHLIKBAZKLZHMJ-WLHGVMLRSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.7
  • 重原子数:
    25
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.44
  • 拓扑面积:
    124
  • 氢给体数:
    2
  • 氢受体数:
    8

文献信息

  • [EN] ARYL IMIDAZOLE COMPOUNDS AND THEIR USE AS BETA AMYLOID PRODUCTION INHIBITORS<br/>[FR] COMPOSÉ ARYLIMIDAZOLE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE PRODUCTION DE LA PROTÉINE AMYLOÏDE BÊTA
    申请人:EISAI R&D MAN CO LTD
    公开号:WO2010098488A1
    公开(公告)日:2010-09-02
    A compound represented by the formula (I): or a pharmacologically acceptable salt or ester thereof, wherein Ring A represents a triazolyl group or the like which may be substituted, Ring B represents a phenyl group or the like which may be substituted, X1 represents a single bond or the like, R1 and R2 each represent a C1-6 alkyl group or the like, m represents an integer of 0 to 3, and n represents an integer of 0 to 2, is effective as a therapeutic agent for a disease caused by Aβ.
    一种由化学式(I)表示的化合物,或其药理学上可接受的盐或酯,其中环A代表可能被取代的三唑基团或类似物,环B代表可能被取代的苯基团或类似物,X1代表单键或类似物,R1和R2分别代表C1-6烷基或类似物,m代表0到3的整数,n代表0到2的整数,对于由Aβ引起的疾病具有治疗作用。
  • MULTI-CYCLIC COMPOUNDS
    申请人:KIMURA Teiji
    公开号:US20090062529A1
    公开(公告)日:2009-03-05
    A compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein Ar 1 represents an imidazolyl group or the like which may be substituted with a C1-6 alkyl group, Ar 2 represents a phenyl group or the like which may be substituted with a C1-6 alkoxy group, X 1 represents a double bond or the like and Het represents a triazolyl group or the like which may be substituted with a C1-6 alkyl group or the like, is effective as a therapeutic or prophylactic agent for a disease caused by Aβ.
    一种由化学式(I)表示的化合物或其药理学可接受的盐,其中Ar1代表可用C1-6烷基基团取代的咪唑基团或类似基团,Ar2代表可用C1-6烷氧基团取代的苯基团或类似基团,X1代表双键或类似基团,Het代表可用C1-6烷基基团或类似基团取代的三唑基团或类似基团,对由Aβ引起的疾病具有治疗或预防作用。
  • [EN] NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS BETA AMYLOID PRODUCTION INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES CONDENSÉS CONTENANT DE L'AZOTE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE PRODUCTION DE LA BÊTA-AMYLOÏDE
    申请人:EISAI R&D MAN CO LTD
    公开号:WO2010098487A1
    公开(公告)日:2010-09-02
    A compound represented by the formula [I]: or a pharmacologically acceptable salt or ester thereof, wherein Ring A represents a five-membered aromatic heterocyclic group or the like fused with a non-aromatic ring group, which may be substituted, Ring B represents a phenyl group or the like which may be substituted, X1 represents a single bond or the like, R1 and R2 each represent a C1-6 alkyl group or the like, m represents an integer of 0 to 3, and n represents an integer of 0 to 2, is effective as a therapeutic agent for a disease caused by Aβ.
    化合物的分子式为[I]:或其药理学可接受的盐或酯,其中环A代表一个五元芳香杂环基团或类似于非芳香环基团的融合物,可以被取代,环B代表一个苯基或类似的基团,可以被取代,X1代表一个单键或类似物,R1和R2分别代表一个C1-6烷基基团或类似物,m表示0到3的整数,n表示0到2的整数,对由Aβ引起的疾病具有治疗作用。
  • [EN] IMIDAZOLYLPYRAZINE DERIVATIVES<br/>[FR] DÉRIVÉS D'IMIDAZOLYLPYRAZINE
    申请人:EISAI R&D MAN CO LTD
    公开号:WO2010098495A1
    公开(公告)日:2010-09-02
    To provide a novel low-molecular-weight compound that inhibits the production of amyloid-β (Aβ ). A compound represented by the formula [I]: or a pharmacologically acceptable salt or ester thereof, wherein R1 and R2 are the same or different and each represent a substituent selected from the following Substituent Group a1; m represents an integer of 0 to 3; n represents an integer of 0 to 2; X1 represents a single bond or the like; X2 represents a single bond or the like; Ring A represents a five-membered aromatic heterocyclic group or the like which contains two or more nitrogen atoms and may have 1 to 3 substituents selected from the following Substituent Group b1; and Ring B represents a monocyclic or fused cyclic aromatic ring group such as the formula [2] which may have 1 to 3 substituents selected from the following Substituent Group c1, is effective as a therapeutic agent for a disease such as Alzheimer's disease. Substituent Group a1: a C1-6 alkyl group and the like Substituent Group b1: a C1-6 alkyl group and the like Substituent Group c1: an amino group and the like
    提供一种新型低分子量化合物,该化合物能够抑制淀粉样蛋白-β(Aβ)的产生。表示为化学式[I]的化合物,或其药理学上可接受的盐或酯,其中R1和R2相同或不同,每个代表以下取代基团a1中选择的取代基;m代表0到3的整数;n代表0到2的整数;X1代表单键或类似物;X2代表单键或类似物;环A代表含有两个或更多氮原子并且可能具有1到3个取代基团b1中选择的取代基的五元芳香杂环基团或类似物;环B代表可能具有1到3个取代基团c1中选择的取代基的单环或融合环芳香环基团,如化学式[2]所示,对于阿尔茨海默病等疾病具有治疗作用。取代基团a1:C1-6烷基基团等;取代基团b1:C1-6烷基基团等;取代基团c1:氨基团等。
  • Nitrogen-Containing Fused Heterocyclic Compounds and Their use as Beta Amyloid Production Inhibitors
    申请人:Kitazawa Noritaka
    公开号:US20120053171A1
    公开(公告)日:2012-03-01
    A compound represented by the formula [I]: or a pharmacologically acceptable salt or ester thereof, wherein Ring A represents a five-membered aromatic heterocyclic group or the like fused with a non-aromatic ring group, which may be substituted, Ring B represents a phenyl group or the like which may be substituted, X1 represents a single bond or the like, R1 and R2 each represent a C1-6 alkyl group or the like, m represents an integer of 0 to 3, and n represents an integer of 0 to 2, is effective as a therapeutic agent for a disease caused by Aβ.
    化合物的化学式为[I],或其药理学上可接受的盐或酯,其中环A代表一个五元芳香杂环基团或类似物,与非芳香环基团融合,可以被取代,环B代表苯基或类似物,可以被取代,X1代表单键或类似物,R1和R2各代表C1-6烷基或类似物,m代表0至3的整数,n代表0至2的整数,该化合物对由Aβ引起的疾病具有治疗作用。
查看更多

同类化合物

(2R,3S,5R)-5-(4-氨基-7H-吡咯[2,3-D]嘧啶-7-基-2 -(羟甲基)四氢呋喃-3-醇 鲁索替尼 鲁索利尼杂质C 迪高替尼 诺那吡胺 螺[4.4]壬烷-1-酮,6-氨基-,(5S,6S)- 苯酚,2,4-二氯-5-肼-,单盐酸 苯并呋喃,2,3-二氢-3-(1-甲基乙基)- 聚(氧代-1,2-乙二基),a-甲基-w-[[3,4,4,4-四氟-2-[1,2,2,2-四氟-1-(三氟甲基)乙基]-1,3-二(三氟甲基)-1-丁烯-1-基]氧代]- 维贝格龙 磷酸鲁索替尼 甲基7-(2-甲氧基乙基)-1,3-二甲基-2,4-二羰基-2,3,4,7-四氢-1H-吡咯并[2,3-D]嘧啶-6-羧酸酯 托法替尼杂质28 托法替尼杂质2 托伐替尼杂质T 异丙基2-氨基-4-甲氧基-7h-吡咯并[2,3-d]嘧啶-6-羧酸 巴里替尼杂质5 巴瑞替尼 巴瑞克替尼杂质 巴瑞克替尼中间体3 巴瑞克替尼中间体1 外消旋鲁替替尼-d8 培美酸 吡啶,1-[(2,5-二甲基苯基)甲基]-1,2,3,6-四氢- 吡咯并[1,2-a]嘧啶-3-羧酸 吡咯并[1,2-F]嘧啶-3-甲酸乙酯 吡咯并[1,2-A]嘧啶-6-羧酸 吡咯并[1,2-A]嘧啶-6-甲醛 叔丁基2-氨基-4-氯-5H-吡咯并[3,4-D]嘧啶-6(7H)-羧酸酯 叔丁基-4-氯-2-吗啉代-7H-吡咯并[2,3-D]嘧啶-7-甲酸甲酯 十二烷-1,12-二基二(苯甲基二甲基铵)二氯化 亚乙基,2-氨基-1-(乙酯基<乙氧羰基>)-2-(甲酰基亚氨基)-,(2Z)-(9CI) 二环[2.2.1]庚-5-烯-2-羧酸,丁基酯,(1R,2R,4R)- [4-(1H-吡唑-4-基)-7H-吡咯并[2,3-D]嘧啶-7-基]甲基特戊酸酯 [3-(4-氨基-7H-吡咯并[2,3-d]嘧啶-7-基)环戊基]甲醇 [1-(乙基磺酰基)-3-[4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基]氮杂环丁烷-3-基]乙腈磷酸盐 S-鲁索替尼 PF-04965842(阿布罗替尼) N-苯基-5H-吡咯并(3,2-d)嘧啶-4-胺 N-苄基-7H-吡咯并[2,3-d]嘧啶-4-胺 N-苄基-5H-吡咯并[3,2-d]嘧啶-4-胺 N-甲基-N-((3S,4S)-4-甲基哌啶-3-基)-7H-吡咯并[2,3-D]嘧啶-4-胺 N-甲基-N-((3R,4R)-4-甲基哌啶-3-基)-7H-吡咯并[2,3-D]嘧啶-4-胺 N-甲基-7h-吡咯并[2,3-d]嘧啶-4-胺 N-甲基-1-((1R,4R)-4-(甲基(7H吡咯[2,3-D]嘧啶-4-基)氨基)环己基)甲磺酰胺富马酸甲酯 N-(5-溴-4-氯-7H-吡咯并[2,3-d]嘧啶-2-基)-2,2-二甲基-丙酰胺 N-(4-甲氧基苯基)-5H-吡咯并(3,2-d)嘧啶-4-胺 N-(4-氯-7H-吡咯并[2,3-D]嘧啶-2-基)-2,2-二甲基丙酰胺 N-(4-氯-5-碘-7H-吡咯[2,3-D]嘧啶-2-基)-2,2-二甲基丙酰胺 N-(4-氯-5-氰基-7H-吡咯并[2,3-d]嘧啶-2-基)-2,2-二甲基丙酰胺